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Introduction 22
The HIV-1 'accessory proteins' Vif, Vpr, Nef and Vpu deplete host proteins in infected cells, and are 23 required for viral replication in vivo [1] [2] [3] . We previously used unbiased quantitative proteomics to 24 map temporal changes in cellular protein abundance during HIV infection of CEM-T4 T-cells, and 25 identify novel targets of Vpu (SNAT1), Nef (SERINC3/5) and Vif (PPP2R5A-E) [4, 5] . Nonetheless, 26 known accessory protein targets only account for a tiny fraction of all protein changes observed 27 during HIV infection [5] . Since a single accessory protein, Vif, is sufficient to drive global remodelling 28 of the cellular phosphoproteome [5] , we hypothesised that undiscovered targets of the accessory 29 protein, Vpr, might explain a proportion of the remaining protein-level changes. 30
Results

31
Vpr is required for global proteome remodelling in HIV infected cells. 32 We compared total proteomes of uninfected cells with cells infected with either WT HIV or an HIV 33
Vpr deletion mutant (HIV ∆Vpr) at an infectious MOI of 1.5 (Figure 1A) , resulting in approximately 34 75% infection (Figure 1B) . Data from this experiment are available, together with the other 35 proteomics datasets presented here, in a readily searchable interactive format in Figure 1 -source 36 data 1. Amongst the 7,774 quantitated proteins, we observed widespread changes in cells infected 37 with wild-type HIV (Figure 1C left panel) . Together with known Nef, Vpu and Vif, targets, we saw 38 (Figure 2 -figure supplement 3B) . Depletion of DCAF1 alone did not phenocopy the Vpr mediated 80 proteome remodelling, and the widespread effects of Vpr are therefore unlikely to be only 81 dependent on the Vpr mediated sequestration and/or depletion of DCAF1. As a proportion of 82 cellular DCAF1 was still expressed, known Vpr effects including degradation of HLTF and 83 upregulation of CCNB1 was partially rather than completely inhibited (Figure 2 -figure supplement  84 C). Consistent with this, Vpr mediated changes were broadly reduced in magnitude in the DCAF1 85 knockdown cells (Figure 2 -figure supplement 3D) . Thus, as with depletion of known Vpr targets, 86
extensive Vpr-dependent proteomic remodelling is dependent on Vpr's interaction with its cognate 87 DCAF1/DDB/Cul4 ligase. 88
Residues E24, R36, Y47, D52 and W54 of Vpr are also required for the recruitment and degradation 89 of previously described Vpr targets, and are reported to form the substrate-binding surface [7, 18, 90 19]. Y47, D52 & W54 make up the proposed DNA mimicking motif by which Vpr binds the cellular 91 target UNG2 [18] . In agreement, the Vpr E24R, R36P and Vpr W54R mutants showed attenuated 92 remodelling of the proteome, while a triple mutant, Vpr Y47A, D52A, W54R , was defective for almost all 93
Vpr-dependent protein changes (Figure 2D,E) . Global protein remodelling therefore depends on 94 both the substrate binding surfaces of Vpr, and the recruitment of DCAF1, suggesting that this 95 process is mediated by recruiting Vpr substrates to the DCAF1/DDB1/CUL4 E3 ligase complex, and 96 their subsequent degradation. 97
Vpr causes G2/M arrest in cycling cells, but the mechanism is contentious [9, 13, [20] [21] [22] [23] [24] [25] [26] , as is the 98 connection to any replicative advantage Vpr provides in vivo. To investigate this important issue, we 99 took advantage of previously characterised Vpr mutants. Residue S79 of Vpr is required for Vpr-100 dependent cell cycle arrest [27] (Figure 2D and Figure 2 -figure supplement 1) . Of the other 101 mutants we tested, Vpr Q65R and Vpr Y47A, D52A, W54R mutants are also unable to cause G2/M arrest, while 102 Vpr E24R, R36P has an intermediate phenotype, and Vpr W54R caused G2/M arrest at wild type levels 103
( Figure 2D and Figure 2 -figure supplement 1) . Strikingly, most Vpr-dependent protein changes 104
were also observed with the Vpr S79A mutant (Figure 2D, E) , and are therefore independent of G2/M 105 cell cycle arrest. The presence or absence of G2/M arrest was also a poor correlate of proteomic 106 remodelling across the entire panel of mutants. Cell cycle arrest therefore only explains a minority of 107
Vpr-dependent changes (Figure 2D,E) . 108
Further, previous datasets/reports investigating gene and protein expression during the cell cycle 109 have identified proteins increased or depleted during different phases of the cell cycle, or in 110 chemically G2/M arrested cells [28, 29] (Figure 2 -figure supplement 4) . Cells arrested in G2 using a 111 PLK1 inhibitor show similar regulation of the cyclin family of proteins (Figure 2 -figure supplement  112  4B) , but there is little other correlation between these datasets. Thus, whilst some changes in 113 protein levels induced by Vpr may be explained by the effects of cell cycle arrest, proteins regulated 114 by cell cycle in these datasets only account for a small fraction of Vpr-dependent changes (Figure 2 -115 figure supplement 4A,C,D). 116
Within this minority of changes that correlate with Vpr mediated G2/M arrest, depleted proteins 117 may either represent secondary effects of alteration to the cell cycle, or may correspond to proteins 118 depleted by Vpr, resulting in G2/M arrest. For example, MCM10 has previously been identified as a 119 direct target for Vpr mediated depletion, and it was also reported that depletion of MCM10 by Vpr is 120 at least partly responsible for Vpr mediated G2/M arrest [9] . We found that depletion of MCM10 121 140
To identify those proteins targeted directly by Vpr, we first adopted a co-immunoprecipitation 141 approach (Figure 4A) . Cells were transduced with a 3xHA tagged Vpr lentivirus in the presence of an 142
shRNA to DCAF1 and the pan-cullin inhibitor MLN4924, to minimise substrate degradation and allow 143 successful co-immunoprecipitation. Factors specifically co-immunoprecipitated in the presence of 144
Vpr are expected to include direct Vpr targets and, accordingly, were enriched for proteins depleted 145
(rather than increased) in the presence of Vpr (Figure 4B,D,E) . However, the co-IP was dominated by 146 DCAF1, a stable binding partner of Vpr, identified with a signal intensity 2 orders of magnitude 147 greater than all other proteins (Figure 4C) . This is despite the knockdown of DCAF1 in these cells, 148
which reduces the DCAF1 protein abundance by approximately 50% (Figure 2 -figure supplement  149  3B ). In addition, at least 13 of the proteins co-immunoprecipitating with Vpr are reported to 150 physically interact with DCAF1 alone [30] [31] [32] , of which 11 are not regulated by Vpr, and two, CEP78 151 and IQGAP2, are upregulated by Vpr, explaining their presence in this list of proteins. 152
This mismatch between the high abundance of DCAF1 and the relatively low abundance of direct Vpr 153 targets for degradation is reminiscent of previous reports, which have also found that MS-IP based 154 techniques are ideal for the identification of the cellular machinery co-opted by viral proteins, but 155 often struggle to identify cellular targets, which interact transiently and in competition with each 156 other [33, 34] . We therefore adopted an alternative, pulsed-Stable Isotope Labelling with Amino 157 Acids in Cell Culture (pulsed-SILAC) approach to identify host proteins specifically destabilised within 158 6 hrs of exposure to Vpr (Figure 5A ). This technique is directly analogous to a traditional pulse-chase 159 experiment using radiolabelled methionine/cysteine, but allows a global, unbiased analysis of 160 potential cellular targets [35] . Since proteins are fully labelled prior to exposure to Vpr, differences in 161 abundances of labelled proteins between conditions exclusively reflect changes in protein 162 degradation rates. 163 Six hours after exposure to Vpr, the stability of most proteins was unchanged (Figure 5B , top panel). 164
However, a subset of proteins depleted by Vpr were already destabilised, consistent with Vpr-165 dependent proteasomal degradation. These 27 proteins, including HLTF, are therefore very likely to 166 represent direct targets for Vpr-mediated depletion (Figure 5C) which Vpr interacts with diverse cellular proteins and pathways, perhaps resulting in cumulative or 185 redundant effects on cellular phenotypes. This model does not contradict any single mechanism, but 186
suggests that several are involved. To test this, we investigated the best described phenotype for 187
Vpr, cell cycle arrest at the G2/M phase. As noted, MCM10 degradation correlated with the extent of 188 G2/M arrest in the panel of Vpr mutants tested, and that RNAi for MCM10 results in G2/M arrest, as 189 previously described [9] . We therefore interrogated the Vpr mutant panel dataset (Figure 2) for 190 other direct targets of Vpr mediated degradation described in Table 1 that correlated with the 191 extent of G2/M arrest. 14 proteins with a significant relationship (a linear regression analysis with p 192 < 0.05) ( Figure 6A ) were identified. We tested if their shRNA-mediated depletion could phenocopy 193
Vpr by inducing cell cycle arrest at G2/M ( Figure 6A ). Depletion of 3 Vpr targets: SMN1, CDCA2 and 194 ZNF267 caused G2/M arrest, and these phenotypes were confirmed with a second shRNA ( Figure  195 6C). We suggest that depletion of multiple cellular Vpr targets contribute to the Vpr-mediated G2/M 196 arrest, consistent with our proposed model. 197
Conservation of Vpr targets across primate lentiviruses. 198
Targeting of key cellular proteins such as BST2 or the APOBEC3 family is conserved across multiple 199 lentiviral lineages, demonstrating the in vivo selective advantage of these interactions. We therefore 200 tested a diverse panel of lentiviral Vpr proteins to determine if they shared activity with the NL4-3 201
Vpr variant used in all the experiments above. We included Vpr variants from primary isolates of 202
HIV-1 from two distinct cross-species transmissions from apes to humans (Group M and Group O), in 203 addition to a closely related SIVcpz variant. We also tested Vpr variants from divergent primate 204 lineages, including HIV-2, SIVsmm, SIVagm and SIVrcm (Figure 7A and Figure 7 -figure supplement 205 1). In addition to Vpr, which is present in all primate lentiviruses, viruses of some lineages also bear 206 Vpx, a gene duplication of Vpr. Since depletion of some substrates switches between Vpr and Vpx in 207 lineages bearing this accessory gene, we also included a Vpx variant from Extensive Vpr-dependent remodelling of the cellular proteome was conserved across the HIV-209 1/SIVcpz lineage (Figure 7B -top row). Vpr variants from other lineages showed a narrower set of 210 changes, but the depletion of some proteins, particularly those most heavily depleted by HIV-1, was 211 conserved by Vpr variants across multiple lineages (Figure 7B,C) . Depletion of selected proteins for 212 which commercial antibody reagents were available was readily confirmed by immunoblot of cells 213 transduced with an overlapping panel of Vpr variants (Figure 7D) . Conserved targets of direct Vpr-214 mediated degradation (highlighted in Figure 7C and Figure 7 -figure supplement 1) are therefore 215 likely to provide an in vivo replicative advantage for all primate lentiviruses. 216
While none of the identified HIV-1 Vpr targets were degraded by the HIV-2 Vpx (HIV-2 ROD ) tested, we 217 noted a shared ability of HIV-2 Vpx and SIVagm Vpr to deplete TASOR, a critical component of the 218
Human Silencing Hub (HuSH) transcription repressor complex we recently described [41] (Figure 8) .
219
The HuSH complex mediates position-dependent transcriptional repression of a subset of lentiviral 220
integrations, and antagonism of HuSH is able to potentiate HIV reactivation in the J-LAT model of 221 latency [41] . As predicted, Vpx-VLPs phenocopied the effect of RNAi-mediated TASOR depletion on 222 reactivation of the HuSH-sensitive J-LAT clone A1 ( Figure 8B) . With some exceptions, most primate 223 lentiviruses can be categorised into 5 lineages (Figure 8C) , of which two encode Vpx. The previously 224 described canonical function of Vpx is the degradation of SAMHD1 [42, 43] . Two lentiviral lineages 225 lack Vpx, but use Vpr to degrade SAMHD1, while the HIV-1/SIVcpz lineage lacks SAMHD1 antagonism 226 [44] . We considered that TASOR antagonism may follow the same pattern, and thus tested Vpx 227 proteins from both Vpx bearing lineages, and representative Vpr variants from lineages that use Vpr 228 to degrade SAMHD1. All of these proteins were able to deplete TASOR in Vpx/Vpr transduced cells 229 ( Figure 8D ). Antagonism of SAMHD1 and TASOR therefore follow the same pattern. Whilst this 230 manuscript was in preparation, two other groups independently discovered Vpx-mediated depletion 231 of TASOR [45, 46] , and the role of HuSH antagonism in lentiviral infection is the subject of ongoing 232 investigation. 233
While the targeting of some substrates was conserved across Vpr varients from multiple lineages, we 234 did not observe broad proteome remodelling outside the HIV-1/SIVcpz lineage. However, in the 235 experiment described in Figure 7 an HIV-1 based lentiviral transduction system was used. Of the Vpr 236
and Vpx variants tested, only Vpr protein from only the HIV-1/SIVcpz alleles are efficiently packaged. 237
In these cases, cells receive both incoming and de novo synthesized Vpr, while in the case of other 238 variants tested, only de novo synthesized Vpr is present. There is therefore a time-lag of at 18-24 239 hours for viral entry, reverse transcription, integration and de novo synthesis of protein to begin. As 240 such, the more limited proteome remodelling seen in Vpr variants may reflect a lack of time for such 241 changes to occur. 242
In order to account for this, we carried out an experiment in which cells were transduced with a Vpr 243 or Vpx from the primary HIV-2 isolate 7312a and assayed 48 h to 96 hours post transduction ( Figure  244 9A), allowing time for additional changes to develop after de novo Vpr/Vpx synthesis. Even at 96 245 hours post transduction, HIV-2 Vpr showed very limited changes. The majority of these changes 246
consisted of the depletion of proteins described above as being also targeted by HIV-1 Vpr ( Figure  247 9B left panel). Widespread proteome remodelling was not observed, and global regulation of the 248 proteome is therefore unique to the HIV-1/SIVcpz lineage. As the HIV-1/SIVcpz lineage appears to 249 be more pathogenic than other primate lentiviral lineages [47, 48] this activity of HIV-1 Vpr may be 250 significant, particularly given the potential to drive these changes in Vpr exposed but uninfected 251 bystander cells. 252
Curiously, 7312a HIV-2 Vpx depleted several proteins we have identified as being modulated by HIV-253
1 Vpr (Figure 9B -right panel), including direct targets for HIV-1 Vpr mediated degradation, BBX, 254 HASPIN and ARHGAP11A. Some proteins were degraded by both HIV-2 Vpr and Vpx, while others 255 were only degraded by the Vpx of this isolate. In lentiviral strains and/or lineages that encode both 256
Vpr and Vpx, responsibility for degrading key targets of HIV-1 Vpr is therefore shared between Vpr 257
and Vpx, further emphasising their in vivo importance. 258
Discussion
259
Proteomic analyses of cells infected with viruses from different orders have revealed widespread 260
and varied changes to the cellular proteome [5, [49] [50] [51] . While these changes are presumed to be 261 multifactorial, in the case of HIV-1 infection, the majority can be attributed to the action of a single 262 viral protein, Vpr. We propose that this massive cellular proteome remodelling consist of firstly, the 263 direct targeting of multiple cellular proteins for proteosomal degradation via the 264 DCAF1/DDB1/CUL4A E3 ligase complex, followed by resulting secondary effects on other proteins. 265
While many of the changes caused by Vpr are secondary, these changes occur within 48 hours of 266 infection or exposure to Vpr, the physiological timeframe of productively infected T-cell [52, 53] , and 267 are therefore relevant to our understanding of the HIV-1 infected cell. 268
The list of direct targets for Vpr mediated depletion was already extensive. We have confirmed here 269
the Vpr mediated depletion of previously described Vpr targets HLTF [6, 7] targets, proven to the same standard of evidence as previously described direct substrates. 310
However, in our proposed model, Vpr binds and degrades multiple cellular proteins, with the total 311 pool of Vpr shared over multiple targets. The identification of cellular targets by co-IP is thus 312 technically problematic and more prone to false negatives compared to other proteins that establish 313
interactions with a small number of binding partners. We therefore propose an alternative method 314 of identifying direct targets for Vpr mediated depletion -proteins that are post-translationally 315 degraded within 6 hours of treatment with Vpr. This strategy was more successful at capturing the 316 known effects on cellular Vpr targets than the MS-IP approach, with the degradation of HLTF and 317
ZGPAT being demonstrated within 6 hours of Vpr exposure. We are confident that the other proteins 318 identified in this fashion also represent direct targets for Vpr mediated degradation, as secondary 319 effects are excluded by both intrinsic elements of the technique, and the short time frame allowed. 320
A comparison of this work with the recent publication by Lapek et al [14] is required, given the major 321 differences between these studies, despite apparent similarities in the approach. Lapek et al use an 322
inducible HIV-1 provirus and quantify changes to the cellular proteome up to 24 hours post 323 activation. They compare a wild type and a Vpr deficient provirus but find fewer differences than in 324 this study -indeed, they identify only nine proteins with significant difference between wild type 325 and dVpr, none of which are previously defined Vpr targets -although DCAF1 is significantly reduced 326
in the presence of Vpr. The difference most likely relates to differences between the systems used. 327
In our model system, as in physiological conditions, Vpr is delivered with the virus particle at '0 h' 328 but de novo production of Vpr occurs late in the virus lifecycle. In Lapek et al, The experiment is 329 concluded 24 hours after induction of the provirus. As production of de novo Vpr is Rev-dependent, 330
Vpr production must occur after a significant delay within that 24-hour period. Thus, while some 331 limited primary effects are evident such as the depletion of DCAF1, other primary and secondary 332 effects may not have had time to occur. Aside from the matter of timing, it is also worth noting that 333 that in the Lapek which Vpr or Vpx expression is driven by the rous sarcoma virus (RSV) promotor, and Emerald GFP 391 expression is driven by the ubiquitin promotor. Virus was generated by co-transfection with p8.91 392 and pMD.G in 293T as previously described [5] . Infectious MOI was normalised by infection in the 393 absence of reverse transcription (RTi) inhibitors, which were included where specified (see below). 394
The panel of Vpr and Vpr proteins used are detailed in Table 2 . Amino acid sequences were codon 395 optimized and synthesized as double stranded DNA (IDT), inserted into the empty vector construct 396
by Gibson assembly, and confirmed by sanger sequencing. 397
CEM-T4 T-cell infections 398
CEM-T4 T-cells were infected with concentrated NL4-3-dE-EGFP or pHRSIN lentiviral stocks by 399 spinoculation at 800 ×g for 1 h in a non-refrigerated benchtop centrifuge in complete media 400 supplemented with 10 mM HEPES. Where reverse transcription treatment was specified (RTi), cells 401
were incubated with zidovudine (10 μM) and efavirenz (100 nM At 0 h, cells were washed in media containing only light ( 12 C / 14 N) lysine and arginine and were 413 maintained in this media for the duration of the experiment. Additional detail on MS methods is 414 available at the end of this section. 415
Lentivector for shRNA expression 416
For lentiviral shRNA-mediated knockdown of DCAF1 hairpins were cloned into pHRSIREN-PGK-hygro, 417
with transduced cells selected for hygromycin resistance. 418
The following oligonucleotide was inserted using BamHI-EcoRI (only top oligonucleotide shown), 419
identified from the Broad Institute GPP Web portal. Gene specific target sequence (forward and 420 reverse complement) is underlined. 421
DCAF1
GATCCGCTGAGAATACTCTTCAAGAATTCAAGAGATTCTTGAAGAGTATTCTCAGCTTTTTTG 423
The same methodology was used to clone other shRNA haripins, the forward orientation targeting 424 sequence used for each is shown below. 425
MCM10-1 AGATGCAGGAGCGCTACTTTG
CGAGAAACAGAAACGTAAGAA
Mass spectrometry Immunoprecipitation (MS-IP) 426
CEM-T4 T-cells were lysed in 1 % NP-40. Lysates were pre-cleared with IgG-Sepharose (GE 427
Healthcare, UK) and incubated for 3 hr at 4°C with anti-HA coupled to agarose beads (Sigma EZview 428
Red Anti-HA Affinity Gel). After washing in 0.5% NP-40, samples were eluted with 0.5 mg/ml HA 429 peptide at 37°C for 1 hr. Additional detail on MS methods is available at the end of this section. 430
Proteins defined as co-immunoprecipitating with Vpr were detected with at least 3 peptides in the 431
Vpr condition, not identified in the control condition, and were present in <20% of MS-IP available in 432
the Crapome [68] database http://crapome.org/. 433
Antibodies 434
Antibodies against the following proteins were used for immunoblot, listed by manufacturer: Atlas 435 antibodies: TASOR (HPA006735). Bethyl: BBX (A303-151A), HLTF (A300-230A), RALY (A302-070A), 436 ZNF512B (A303-234A). Cell signalling : SMN1/2 (2F1). Novus: ESCO2 (NB100-87021). Origine: UNG2 437 (2C12). Proteintech: Vpr (51143-I-AP). Santa Cruz: CCNB1 (SC-245), ZGPAT (SC-51524). Sigma: β-actin 438 (AC74). Abcam : p24 (ab9071), VCP (ab11433). The following secondary antibodies were used: goat 439
anti-mouse-HRP and anti-rabbit-HRP (immunoblot, Jackson ImmunoResearch, West Grove, PA). Anti-440
CD4-AF647 (clone OKT4; BioLegend) and anti-CD271 (NGFR)-APC (clone ME20.4, Biolegend) were 441 used for flow cytometry. 442
J-LAT reactivation experiments.
443
JLAT A1 cells were transduced with Cre recombinase, NL4-3 Vpr or HIV-2 ROD Vpx within a pHRSIN 444 IRES NGFR vector [69] . 24 h after transduction, cells were treated with 2 ng/ml TNFα (PeproTech, 445 300-01A). After an additional 24 h cells were stained with anti-NGFR APC and analysed for APC and 446 GFP expression by flow cytometry. Cells were gated for NGFR+ cells to exclude non-transduced cells. 447
Flow cytometry data was acquired on a BD FACSCalibur. 448
Statistical analysis 449
Anova and Fisher's exact test analysis were carried out as described in figure legends using 450
Graphpad Prism (v7.04 with cycling parameters of 50°C for 2 min and 95°C for 5 min, followed by 40 cycles of 95°C for 15 s 469 and 60°C for 1 min. The gene-of-interest specific primer pairs were predesigned and purchased from 470
Sigma-Aldrich as KiCqStart primers, with the following sequences: MCM10_FOR 5′-471 CTTATACAGAAGAGGCTGATG and MCM10_REV 5'-CCTCTTGCAACTCTTCATTC; ZNF267_FOR 5'-472 GTAGAATTCTCTTTGGAGGAG and ZNF267_REV 5'-CTCACTCTTCACATTCCAAG; CDCA2_FOR 5'-473 AGGAAAGTCATCATCCTACC and CDCA2_REV 5'-GATGGTTTGTTTCAGGAGAG; SMN1_FOR 5'-474
GGAAAGCCAGGTCTAAAATTC and SMN1_REV 5'-AGAATCTGGACATATGGGAG. The difference in the 475 amount of input cDNA was normalized to an internal control of GAPDH, using the following primers: 476 GAPDH_FOR: 5' ATGGGGAAGGTGAAGGTCG and GAPDH_REV: 5′-CTCCACGACGTACTCAGCG. 477 UV was monitored at 280 nm. Samples were loaded in 90% A for 10 min before a gradient elution of 519 0-10% B over 10 min (curve 3), 10-34% B over 21 min (curve 5), 34-50% B over 5 mins (curve 5) 520
followed by a 10 min wash with 90% B. 15 s (100 µL) fractions were collected throughout the run. 521
Peptide containing fractions were orthogonally recombined into 24 fractions (i.e. fractions 1, 25, 49, 522 73, 97 combined) and dried in a vacuum centrifuge. Fractions were stored at −80°C prior to analysis. 523
Mass spectrometry 524
Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an 525
Ultimate 3000 RSLC nano UHPLC (Thermo Scientific). HpRP fractions were resuspended in 20 µl 5% 526 DMSO 0.5% TFA and 10uL injected. Fractions were loaded at 10 μl/min for 5 min on to an Acclaim 527
PepMap C18 cartridge trap column (300 um × 5 mm, 5 um particle size) in 0.1% TFA. After loading a 528 linear gradient of 3-32% solvent B was used for sample separation over a column of the same 529 stationary phase (75 µm × 50 cm, 2 µm particle size) before washing at 90% B and re-equilibration. 530
Solvents were A: 0.1% FA and B:ACN/0.1% FA. 3h gradients were used for whole cell proteomics 531 samples, 1h gradients for MS-IPs. 532
An SPS/MS3 acquisition was used for TMT experiments and was run as follows. MS1: Quadrupole 533 isolation, 120'000 resolution, 5e5 AGC target, 50 ms maximum injection time, ions injected for all 534 parallelisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation 535 (NCE 35) with the ion trap scanning out in rapid mode from m/z 120, 8e3 AGC target, 70 ms maximum 536 injection time, ions accumulated for all parallelisable time. In synchronous precursor selection mode 537 the top 10 MS2 ions were selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at 538 50'000 resolution with an AGC target of 2e4 and a maximum accumulation time of 120 ms, ions were 539 not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. 540
Dynamic exclusion was set to +/−10 ppm for 90 s, MS2 fragmentation was trigged on precursor ions 541 5e3 counts and above. For MS-IPs, MS2 instead used HCD fragmentation (NCE 34) and a maximum 542 injection time of 250ms and had a target cycle time of 2s. For pSILAC MS1 was acquired at 240'000 543 resolution. 544
Data processing and analysis 545
For TMT labelled samples data were searched by Mascot within Proteome Discoverer 2.1 in two 546 rounds of searching. First search was against the UniProt Human reference proteome (26/09/17), the 547
HIV proteome and compendium of common contaminants (GPM). The second search took all 548 unmatched spectra from the first search and searched against the human trEMBL database (Uniprot, 549 26/09/17). The following search parameters were used. MS1 Tol: 10 ppm, MS2 Tol: 0.6 Da. Enzyme: 550 Trypsin (/P). MS3 spectra were used for reporter ion based quantitation with a most confident 551 centroid tolerance of 20 ppm. PSM FDR was calculated using Mascot percolator and was controlled at 552 0.01% for 'high' confidence PSMs and 0.05% for 'medium' confidence PSMs. Normalisation was 553 automated and based on total s/n in each channel. Protein/peptide abundance was calculated and 554 output in terms of 'scaled' values, where the total s/n across all reporter channels is calculated and a 555 normalised contribution of each channel is output. Proteins/peptides satisfying at least a 'medium' 556 FDR confidence were taken forth to statistical analysis in R. A, Graphical summary of the Vpr viral particle TMT experiment. Three replicates of cells exposed to 782 empty viral particles or Vpr bearing viral particles, along with single replicates of cells exposed to 783 viral particles bearing five different Vpr mutants were prepared and analysed in parallel using TMT 784 labelling. B, Scatterplot displaying pairwise comparison between cells exposed to empty or Vpr 785 bearing viral particles. C, Scatterplot comparing pairwise comparisons from two proteomics 786 experiments, demonstrating the effect of Vpr in the context of HIV-1 infection (x-axis, as shown in 787 Figure 1A ) or through cellular exposure to Vpr protein alone (y-axis, as shown in Figure 2A ). D, 788
Figure legends
scatterplots showing the pairwise comparison between each Vpr mutant tested and empty vector 789 control, with defined groups of 302 Vpr depleted and 413 increased proteins highlighted in blue and 790 red respectively. E, Heatmap showing the behaviour of the 100 proteins most depleted by Vpr 791 particles (blue) and increased (red) within the defined highly modulated subsets. Colour indicates 792 the log 2 fold change of each protein in each condition compared to empty particle treatment. Genes 793 were clustered using uncentered Pearson correlation and centroid linkage, and conditions clustered 794 by column means. 795 previously identified targets for Vpr mediated degradation, shown in purple. CCNB1 is increased by 799
Vpr (red). B, Scatterplot displaying pairwise comparison between cells exposed to empty or Vpr 800 bearing viral particles. C, Scatterplot comparing pairwise comparisons from two proteomics 801 experiments, demonstrating the effect of Vpr in the context of HIV-1 infection (as shown in Figure  802 1A, x-axis) or through cellular exposure to Vpr protein alone (Figure 2A, y- Figure  806 2. 807 A, Immunoblot of purified virus preparations used to infect cells for the proteomics experiment 808 displayed in Fig 2A. B, Bar chart showing the average scaled abundance of matrix, capsid and 809 integrase peptides detected in the cell lysate by MS. Bars show mean and standard deviation. c, 7-810 AAD stain of cells exposed to empty vector, or Vpr wild type or Vpr mutants. Watson pragmatic 811 modelling was used to identify cells in G1 (blue), S (grey) or G2/M (red) phase. 812 between effects secondary to cell cycle arrest between the two datasets. 829
C, Pie charts showing the overlap between changes in the present study and changes induced by 830
G2/M arrest in Ly, 2015 . Left panel shows the behaviour of all proteins quantified in both the 831 present study (Figure 1A and Figure 2A) Fischer, 2016 , define lists of 115 proteins whose expression peaks in G1/S phase and 174 proteins 842 whose expression peaks in G2/M phase. Pie-charts show the overlap between these lists and (left) 843
all proteins detected in the present study, (middle) proteins defined as being depleted by Vpr, and 844
(right) proteins defined as being increased by Vpr. As in the proteomics dataset, there is some 845 enrichment of proteins with peak expression in G2/M within Vpr increased proteins, and some 846 enrichment of proteins with peak expression in G1/S in Vpr depleted proteins, consistent with some 847 effects being secondary to cell cycle arrest, but these effects are in the minority. 848 previously described Vpr targets, proteins with red text were predicted as potential Vpr targets 893
based on their temporal profile of depletion in Greenwood & Matheson, 2016 [5] . 894 Scatterplots showing the pairwise comparison between each Vpr tested and empty vector control 908 with defined groups of 302 Vpr depleted (blue) and 413 increased (red) proteins highlighted. C, 909
Heatmap showing the behaviour of the 100 proteins most depleted by Vpr particles (blue) and 910
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